A unique patch which sticks to the moist surface inside of your mouth is revolutionizing the treatment of painful recurring ulcers. The novel patch slowly releases steroids straight on to oral ulcers and forms protective barrier. Polymers allow it to stick to the moist surface in the mouth.
The plaster releases steroids directly on to oral ulcers or lesions whilst also creating a protective barrier around the affected area, to accelerate healing.
1-2 percent of the population suffer from recurrent mouth diseases known medically as recurrent aphthous stomatitis (RAS), that cause painful lesions such as oral lichen planus (OLP) a rash which causes burning and sore gums and can last for several years in the mouth.
Nowadays the methods for treating ulcers and lesions making them less effective. “Current treatments consist of using steroids in the form of mouthwashes, creams or ointments, but these are often ineffective due to inadequate drug contact times with the lesion,” said Dr Craig Murdoch, lead author of the research. “Chronic inflammatory conditions such as OLP and RAS, which cause erosive and painful oral lesions, have a considerable impact on quality of life.”
The novel patch is a breakthrough therapy for the treatment of all kind of ulcers, which can range from 2 to 10mm in diameter and can last from two to six weeks, appearing in clusters of up to 30 at a time in some cases.
“The patch acts like a plaster inside your mouth, which means it is very effective at directly targeting the specific area as well as forming a protective barrier. Patients who have trialed the patch found it to be very comfortable to wear and they were really pleased with the length of adhesion which makes it particularly effective and efficient,” Murdoch said.
The scientists were working in close collaboration with Dermtreat A/S from Copenhagen. The company is going ahead with the biodegradable Rivelin patch technology after receiving £13.3million ($17.7million) in venture capital investment.
Dermtreat CEO, Jens Hansen, added: “Our company is very confident that we will soon gain regulatory approval for the first adhesive drug delivery technology to address pressing clinical needs in oral medicine. We look forward to continuing this collaboration, which will be increasingly directed at finding new clinical applications for muco-adhesive patches.”